Antimicrobial Resistance Surveillance Global Market Report 2025

The antimicrobial resistance surveillance market size has grown strongly in recent years. It will grow from $6.77 billion in 2024 to $7.36 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increased use of antibiotics in agriculture, the overprescription of antibiotics in healthcare, a lack of diagnostic testing, inadequate infection prevention and control practices, and the impact of global travel and trade.

The antimicrobial resistance surveillance market size is expected to see strong growth in the next few years. It will grow to $10.18 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing awareness of antimicrobial resistance, advancements in diagnostic technologies, rising government initiatives and funding, a surge in healthcare-associated infections, and the development of new antibiotics and alternative treatments. Key trends include the use of artificial intelligence for data analysis, next-generation sequencing technologies, real-time surveillance systems, molecular diagnostic tools, and the integration of big data and machine learning for predictive modeling.

The increasing prevalence of infectious diseases is expected to drive the growth of the antimicrobial resistance surveillance market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites and can spread directly or indirectly between individuals. Factors such as climate change, urbanization, and global travel contribute to the rising prevalence of these diseases by facilitating pathogen transmission and increasing human exposure to new microbes. Antimicrobial resistance surveillance plays a crucial role in tracking the spread of resistant pathogens, guiding effective treatment strategies, and shaping public health policies to combat infectious diseases. For example, in February 2024, a report by the UK Health Security Agency revealed a 10.7% increase in tuberculosis (TB) cases in England, with 4,850 cases reported in 2023 compared to 4,380 in 2022. As a result, the increasing prevalence of infectious diseases is fueling the expansion of the antimicrobial resistance surveillance market.

Leading companies in the industry are focusing on innovative technologies, such as advanced diagnostic tools, to improve efficiency, enhance accuracy, reduce costs, and provide better patient outcomes. A diagnostic tool encompasses any device, instrument, software, or methodology used to detect, identify, or assess the presence of a condition, disease, or malfunction. For instance, in June 2023, Sysmex Astrego AB, a Sweden-based manufacturer of diagnostic products, launched the PA-100 AST Point-of-Care Testing System. This system enables rapid and precise detection of antimicrobial resistance at the point of care, significantly reducing the time required for results compared to conventional laboratory methods, which can take several days. By delivering results in just 30 minutes, it empowers clinicians to make timely and informed decisions regarding infection treatment, minimizing reliance on broad-spectrum antibiotics and aiding efforts to curb antimicrobial resistance.

In January 2024, BioMérieux S.A., a France-based biotechnology company, acquired LUMED for an undisclosed amount. This acquisition is aimed at enhancing BioMérieux’s capabilities in combating antimicrobial resistance and strengthening its portfolio, particularly by offering digital tools to support antibiotic stewardship. LUMED Inc., an Italy-based company, specializes in healthcare and medical data analysis, with a focus on antimicrobial resistance surveillance.

Major players in the antimicrobial resistance surveillance market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, Viatris Inc., Wolters Kluwer NV, Hologic Inc., Biomerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen NV, Cepheid Inc., Shionogi & Co. Ltd., Venatorx Pharmaceuticals Inc., Accelerate Diagnostics Inc., Paratek Pharmaceuticals Inc., Liofilchem Srl, Lumed Inc., OpGen Inc.

North America was the largest region in the antimicrobial resistance surveillance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antimicrobial resistance surveillance report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antimicrobial resistance surveillance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antimicrobial resistance (AMR) surveillance involves the systematic monitoring and tracking of antimicrobial-resistant microorganisms to detect emerging resistance patterns, guide public health interventions, and inform treatment strategies for infections caused by resistant bacteria, viruses, and fungi.

The primary solutions in AMR surveillance include diagnostic kits, diagnostic systems, surveillance software, and services. Diagnostic kits are pre-packaged tools that enable healthcare professionals to rapidly identify antimicrobial-resistant infections in patients. These solutions are applied in clinical diagnostics, public health surveillance, and other areas, serving end users such as hospitals and clinics, research and academic institutes, and other healthcare facilities.

The antimicrobial resistance surveillance market research report is one of a series of new reports that provides antimicrobial resistance surveillance market statistics, including antimicrobial resistance surveillance industry global market size, regional shares, competitors with an antimicrobial resistance surveillance market share, detailed antimicrobial resistance surveillance market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial resistance surveillance industry. This antimicrobial resistance surveillance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antimicrobial resistance (AMR) surveillance market consists of revenues earned by entities by providing services such as diagnostic testing services, surveillance data collection and analysis, antimicrobial stewardship programs, and infection control and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antimicrobial resistance (AMR) surveillance market also includes sales of diagnostic equipment and tools, antimicrobial agents, laboratory instruments, and software and data analytics platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.